For 10,000 years, psilocybin mushrooms were revered as sacred teachers by indigenous cultures across the Americas, Africa, and possibly Europe. For 50 years, they were vilified, criminalised, and scientifically suppressed. Now they are the subject of the most exciting clinical research in psychiatry — with results for depression, addiction, PTSD, and end-of-life anxiety that have stunned the medical establishment. The mushroom is back, and it arrived bearing data.
What Is Psilocybin?
Psilocybin is the prodrug form of psilocin — a serotonergic psychedelic found in over 200 species of fungi, primarily in the genus Psilocybe. After ingestion, the body converts psilocybin to psilocin via dephosphorylation. Psilocin is structurally similar to serotonin and acts primarily as a partial agonist at 5-HT2A receptors — particularly densely expressed in the prefrontal cortex — producing altered states of consciousness lasting 4–6 hours.
It is important to understand that psilocybin is physiologically non-toxic, does not produce physical dependence, and has never been directly implicated in a recorded human death from toxicity. Its primary risks are psychological: the intensity of the experience can trigger panic or psychotic episodes in vulnerable individuals, and the profound dissolution of ordinary ego structures it produces requires appropriate set, setting, and support.
Teonanácatl: Flesh of the Gods
The Aztec name for psilocybin mushrooms was teonanácatl — "flesh of the gods." The Mazatec curandera María Sabina, whose ceremonies in Oaxaca were first documented by R. Gordon Wasson in 1957, described the mushrooms as "children" who spoke directly to her, revealing healing knowledge. The Mixtec mushroom stones — carved stone figures of mushroom-people — date to 3500 BCE in present-day Guatemala. The reverence was not casual; these were among the most sacred substances in Mesoamerican civilisation.
The Neuroscience of Psilocybin
Psilocybin produces what Robin Carhart-Harris at UCSF calls "REBUS" — Relaxed Beliefs Under Psychedelics. The default mode network (DMN), which maintains our ordinary sense of self, identity, and habitual narrative, is dramatically suppressed. Simultaneously, regions of the brain that normally do not communicate establish novel connections — producing the sensation of boundary dissolution, unity, and novel insight that characterises the experience.
The resulting state of maximum neural entropy — the brain operating with unprecedented flexibility and connectivity — appears to be precisely the mechanism by which psilocybin breaks the rigid neural patterns underlying depression, addiction, and OCD. These conditions are characterised by the opposite: inflexible, self-reinforcing neural loops. Psilocybin disrupts the loop.
The REBUS Model
Carhart-Harris & Friston (2019) proposed that psilocybin relaxes the brain's "precision weighting" of prior beliefs — the hierarchical model it uses to interpret reality. Under psilocybin, bottom-up sensory information is no longer filtered through rigid top-down predictions. The result: reality appears vivid, novel, and deeply interconnected. Crucially, the habitual self-concept — the source of rumination, self-criticism, and the "narrative trap" of depression — temporarily dissolves. This is experienced subjectively as ego dissolution; neurologically it maps onto DMN suppression and dramatically increased whole-brain connectivity.
Neuroplasticity and BDNF
Psilocybin has been shown to produce rapid and lasting neuroplastic changes — distinct from the acute experience itself. A 2021 study by Cahart-Harris et al. found that a single psilocybin experience produced measurable increases in synaptogenesis (new synaptic connections) in the prefrontal cortex, measurable weeks after the experience. This structural change may explain why the therapeutic effects of psilocybin persist long after the drug has cleared from the system.
— Terence McKenna
The Clinical Research Revolution
Depression
The Johns Hopkins and Imperial College London trials for treatment-resistant depression have produced results that have genuinely shocked the psychiatric establishment. A 2020 JAMA Psychiatry study found that two psilocybin sessions with psychological support produced response rates of 67% and remission rates of 71% at 4-week follow-up in treatment-resistant depression patients — people who had failed multiple antidepressants. A 2021 randomised controlled trial in the New England Journal of Medicine found psilocybin outperformed escitalopram (a standard SSRI) at 6 weeks on multiple measures of wellbeing, with a more favourable side-effect profile.
Addiction
A 2014 study by Matthew Johnson at Johns Hopkins showed that psilocybin-assisted therapy produced 80% abstinence rates from tobacco at 6-month follow-up — an extraordinary result compared to the ~35% rate for varenicline (the best pharmacological intervention). A 2022 double-blind RCT for alcohol use disorder found psilocybin doubled the number of abstinent days compared to placebo at 32 weeks. These are among the strongest addiction treatment results ever recorded.
End-of-Life Anxiety
A landmark 2016 study at Johns Hopkins and NYU simultaneously found that a single psilocybin session dramatically reduced death anxiety and depression in cancer patients facing terminal diagnoses — with 80% of participants showing clinically significant reductions at 6 months. Many described the experience as among the most meaningful of their lives. The mechanism appears to involve a profound shift in relationship to death: rather than an absolute ending, the ego dissolution of psilocybin provides direct experiential access to a sense of consciousness beyond ordinary identity.
The Mystical Experience Variable
Across multiple studies, the single most reliable predictor of therapeutic outcome from psilocybin is the occurrence of a "complete mystical experience" — a state characterised by feelings of unity, sacredness, deeply felt positive mood, transcendence of time and space, and a sense of encountering ultimate reality. This experience, rated on the Mystical Experience Questionnaire (MEQ30), correlates more strongly with clinical outcome than dose, preparation, or any other variable. This is extraordinary: the mechanism of healing is, by scientific measure, a spiritual experience.
Set, Setting, and Safety
Timothy Leary's maxim that psilocybin's effects are 90% determined by "set and setting" — mindset and environment — has been comprehensively confirmed by research. The same dose in an unsupportive, chaotic environment can produce a psychologically difficult or traumatic experience; in a carefully prepared, supportive ceremonial or therapeutic context, it produces experiences of profound healing and insight.
The clinical protocols developed at Johns Hopkins involve: extensive preparation sessions with trained therapists, intentional ceremonial framing of the experience, trained guides present throughout, a carefully designed room with comfortable furniture, eye shades, and curated music, and multiple integration sessions following. The container is inseparable from the medicine.
Safety and Contraindications
Psilocybin is contraindicated for: personal or family history of psychosis or schizophrenia (serious risk of precipitation), bipolar disorder type 1, and current use of lithium (seizure risk). Significant caution is warranted for those with severe trauma without professional support and for those in acute emotional crisis. Psilocybin is currently a Schedule I substance in the US (legal for therapeutic use in Oregon and Colorado), a Class A drug in the UK, and illegal in most jurisdictions. Decriminalisation and therapeutic access are expanding rapidly. Work only within legal frameworks or authorised clinical trials. This content is educational only.
References
- Davis AK, et al. (2020). Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry, 78(5), 481–489.
- Carhart-Harris R, et al. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384, 1402–1411.
- Johnson MW, et al. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983–992.
- Bogenschutz MP, et al. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo. JAMA Psychiatry, 79(10), 953–962.
- Griffiths RR, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. Journal of Psychopharmacology, 30(12), 1181–1197.
- Carhart-Harris R, Friston K. (2019). REBUS and the anarchic brain. Pharmacological Reviews, 71(3), 316–344.